<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145638</url>
  </required_header>
  <id_info>
    <org_study_id>P-Monofer-CIA-01</org_study_id>
    <secondary_id>EudraCT no. 2009-016727-53</secondary_id>
    <nct_id>NCT01145638</nct_id>
  </id_info>
  <brief_title>A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)</brief_title>
  <official_title>A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacosmos A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of intravenous iron therapy
      with oral iron therapy in patients with cancer and chemotherapy induced anaemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hb Concentration</measure>
    <time_frame>Baseline week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin From Baseline to Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Non-myeloid Malignancies</condition>
  <condition>Chemotherapy Induced Anaemia</condition>
  <arm_group>
    <arm_group_label>iron isomaltoside 1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iron isomaltoside intravenously as bolus or infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iron sulphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral iron sulphate twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iron isomaltoside 1000</intervention_name>
    <description>intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose</description>
    <arm_group_label>iron isomaltoside 1000</arm_group_label>
    <other_name>Monofer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iron sulphate</intervention_name>
    <description>oral, 200 mg per day (100 mg bid),12 weeks</description>
    <arm_group_label>iron sulphate</arm_group_label>
    <other_name>Ferroduretter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, aged more than 18 years.

          2. Subjects diagnosed with cancer (non-myeloid malignancies) receiving chemotherapy at
             least 1 day prior to screening and who are going to receive at least two more
             chemotherapy cycles.

          3. Hb &lt; 12 g/dL (7.4 mmol/L).

          4. TfS &lt;50%.

          5. Serum Ferritin &lt;800 ng/ml.

          6. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to

          7. Willingness to participate after informed consent (including HIPAA, if applicable).

        Exclusion Criteria:

          1. Anemia caused primarily by other factors than CIA.

          2. IV or oral iron treatment within 4 weeks prior to screening visit.

          3. Erythropoietin treatment within 4 weeks prior to screening visit.

          4. Blood transfusion within 4 weeks prior to screening visit.

          5. Imminent expectation of blood transfusion on part of treating physician.

          6. Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and
             haemosiderosis).

          7. Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono- or
             disaccharide complexes or to iron sulfate).

          8. Known hypersensitivity to any excipients in the investigational drug products.

          9. Subjects with a history of multiple allergies.

         10. Decompensated liver cirrhosis or active hepatitis (alanine aminotransferase (ALAT) &gt; 3
             times upper normal limit).

         11. Active acute or chronic infections (assessed by clinical judgement and if deemed
             necessary by investigator supplied with white blood cells (WBC) and C-reactive protein
             (CRP)).

         12. Rheumatoid arthritis with symptoms or signs of active joint inflammation.

         13. Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal (at least
             12 months must have elapsed since last menstruation), surgically sterile, or women of
             child bearing potential must use one of the following contraceptives during the whole
             study period and after the study has ended for at least 5 times plasma biological
             half-life of the investigational medicinal product: Contraceptive pills, intrauterine
             devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal
             implantation, vaginal ring, and transdermal patches).

         14. Planned elective surgery during the study.

         15. Participation in any other clinical study (except chemotherapy protocol) within 3
             months prior to screening.

         16. Known intolerance to oral iron treatment.

         17. Untreated B12 or folate deficiency.

         18. Any other medical condition that, in the opinion of Principal Investigator, may cause
             the subject to be unsuitable for the completion of the study or place the subject at
             potential risk from being in the study. Example, Uncontrolled Hypertension, Unstable
             Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Lykke Thomsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmacosmos A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2010</study_first_submitted>
  <study_first_submitted_qc>June 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <results_first_submitted>September 21, 2015</results_first_submitted>
  <results_first_submitted_qc>November 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2015</results_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>chemotherapy induced anaemia</keyword>
  <keyword>iron</keyword>
  <keyword>Patients with non-myeloid malignancies and Chemotherapy Induced Anaemia (CIA)</keyword>
  <keyword>CIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Hematinics</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Iron Isomaltoside 1000</title>
          <description>Iron isomaltoside intravenously as bolus or infusion
iron isomaltoside 1000: intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose</description>
        </group>
        <group group_id="P2">
          <title>Iron Sulphate</title>
          <description>oral iron sulphate twice a day
iron sulphate: oral, 200 mg per day (100 mg bid),12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Iron Isomaltoside 1000</title>
          <description>Iron isomaltoside intravenously as bolus or infusion
iron isomaltoside 1000: intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose</description>
        </group>
        <group group_id="B2">
          <title>Iron Sulphate</title>
          <description>oral iron sulphate twice a day
iron sulphate: oral, 200 mg per day (100 mg bid),12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="231"/>
            <count group_id="B2" value="119"/>
            <count group_id="B3" value="350"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hb Concentration</title>
        <time_frame>Baseline week 4</time_frame>
        <population>The FAS population included all the subjects who were randomised into the study, received at least one dose of the study drug, and had at least one post-baseline Hb assessment. The subjects were considered as randomised, regardless of which treatment they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000</title>
            <description>Iron isomaltoside intravenously as bolus or infusion
iron isomaltoside 1000: intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose</description>
          </group>
          <group group_id="O2">
            <title>Iron Sulphate</title>
            <description>oral iron sulphate twice a day
iron sulphate: oral, 200 mg per day (100 mg bid),12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hb Concentration</title>
          <population>The FAS population included all the subjects who were randomised into the study, received at least one dose of the study drug, and had at least one post-baseline Hb assessment. The subjects were considered as randomised, regardless of which treatment they actually received.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="-4" upper_limit="4"/>
                    <measurement group_id="O2" value="0.44" lower_limit="-2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin From Baseline to Week 24</title>
        <time_frame>24 weeks</time_frame>
        <population>The FAS population included all the subjects who were randomised into the study, received at least one dose of the study drug, and had at least one post-baseline Hb assessment. The subjects were considered as randomised, regardless of which treatment they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Iron Isomaltoside 1000</title>
            <description>Iron isomaltoside intravenously as bolus or infusion
iron isomaltoside 1000: intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose</description>
          </group>
          <group group_id="O2">
            <title>Iron Sulphate</title>
            <description>oral iron sulphate twice a day
iron sulphate: oral, 200 mg per day (100 mg bid),12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin From Baseline to Week 24</title>
          <population>The FAS population included all the subjects who were randomised into the study, received at least one dose of the study drug, and had at least one post-baseline Hb assessment. The subjects were considered as randomised, regardless of which treatment they actually received.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="-6.3" upper_limit="6.5"/>
                    <measurement group_id="O2" value="1.78" lower_limit="-5.3" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population included all subjects who were randomised and received at least one dose of iron isomaltoside 1000 or iron sulphate. The safety analyses was performed on the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Iron Isomaltoside 1000</title>
          <description>Iron isomaltoside intravenously as bolus or infusion
iron isomaltoside 1000: intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose</description>
        </group>
        <group group_id="E2">
          <title>Iron Sulphate</title>
          <description>oral iron sulphate twice a day
iron sulphate: oral, 200 mg per day (100 mg bid),12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Gastrointestinal polyp haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Unirary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dyspnoe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="229"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="229"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="229"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="229"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="229"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="229"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="229"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="229"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="229"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If Pharmacosmos or its agents has not prepared a draft for submission to a peer reviewed journal prior to 1 year following completion of the study report, the investigators have the right to publish the results. Such publications are to be submitted to Pharmacosmos for comment 30 days prior to submission for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Research &amp; Development Department</name_or_title>
      <organization>Pharmacosmos A/S</organization>
      <phone>+45 59485959</phone>
      <email>llt@pharmacosmos.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

